Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 91

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 91
---
 the pre -fundedwarrants are subject to a beneficial ownership limitation of 4.99% (or upon election of Alpha, 9.99%). Such limitation restricts Alpha from exercising that portion of the warrants that would result in Alpha and its affiliates owning, after exercise, a number of NLS Common Shares in excess of the beneficial ownership limitation. As a result, the number of NLS Common Shares reflected in the table owned by Alpha includes (a) any outstanding NLS Common Shares held by such shareholder, and (b) if any, the number of NLS Preferred Shares and warrants convertible into NLS Common Shares that the holder has the right to acquire within 60 days of July 9, 2025 without such holder or any of such holder’s affiliates beneficially owning more than the beneficial ownership limitation of 9.99%. The address for Alpha is Lettstrasse 32, Vaduz 9490, Liechtenstein. Nicola Feuerstein, a Director of Alpha, holds voting and dispositive power over the securities held by Alpha. At the Closing, 42,220 RSUs issued by Kadimastem are expected to be exchanged for 266,614 RSUs of the combined company, and 175,600 Kadimastem options to purchase Kadimastem Ordinary Shares are expected to be exchanged for 1,108,890 options to purchase NLS Common Shares of the combined company. Q.What is the anticipated ownership of options, warrants and other outstanding equity awards that are anticipated to remain outstanding following the completion of the Merger? As of July9, 2025, the expected total amount of RSUs of Kadimastem that will be exchanged for RSUs of NLS is 42,220 RSUs of Kadimastem, which will equal to 266,614 RSUs of NLS at the Effective Time. All such RSUs have been and shall continue to be owned by current and past officers and employees of Kadimastem, and represent approximately 0.5% of the estimated number of issued and outstanding shares of the combined company immediately following the Closing. As of July9, 2025, the total amount of Kadimastem options that will be exchanged for NLS options at the Effective Time will be 175,600, which will be exchanged for 1,108,890 NLS options. All such options have been and shall continue to be owned by current and past officers and employees of Kadimastem and represent approximately